Rilmenidine hemifumarate (S-3341 hemifumarate) is a novel, orally active and selective I1 imidazoline receptor and α2-adrenoceptor agonist that induces autophagy, regulates the proliferation of leukaemia cells, stimulates the pro-apoptotic protein Bax, and induces autophagy in human leukaemia K5 cells. induces disruption of the mitochondrial pathway and apoptosis in human leukaemia K562 cells.

Rilmenidine具有与利尿剂、β-受体阻滞剂、钙通道阻滞剂和血管紧张素转换酶(ACE)抑制剂相当的降血压效果。Rilmenidine（25-100 μM；24小时）抑制K562细胞增殖[3]。

在使用Rilmenidine治疗的N171-82Q小鼠中（i.p.；每周4次），从12周至22周龄期间，观察到其前肢握力和全身肢体握力显著提升。Rilmenidine还能降低突变huntingtin[2]的水平。